Related Experiment Video

Updated: Jul 4, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Management of advanced adult soft tissue sarcoma

Vivien H C Bramwell1

  • 1Department of Medicine Tom Baker Cancer Centre 1331 - 29th Street N.W. Alberta Calgary T2N 4N2 Canada.

Sarcoma
|June 4, 2008
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Experiment Videos

Last Updated: Jul 4, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.

Breast cancer research : BCR·2014

Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort.

Breast cancer research : BCR·2013

Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.

European journal of cancer (Oxford, England : 1990)·2012

Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

The Lancet. Oncology·2012

Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials.

European journal of cancer (Oxford, England : 1990)·2011

Adjuvant chemotherapy following complete resection of soft tissue sarcoma in adults: a clinical practice guideline.

Sarcoma·2008

Oral Etoposide for Relapsed or Refractory Ewing Sarcoma in Adolescent and Adult Patients.

Sarcoma·2024

Incidence of Undifferentiated Pleomorphic Sarcoma (UPS) in the United States.

Sarcoma·2024

Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients.

Sarcoma·2024

ATRX and Its Prognostic Significance in Soft Tissue Sarcoma.

Sarcoma·2024

Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum.

Sarcoma·2024

Exploring the Diagnostic Dilemma of Indeterminate Pulmonary Nodules in Patients with Primary Sarcoma of Bone.

Sarcoma·2024

Do outcomes diverge over time? A 5-year Spine CORe™ Quality Outcomes Database study comparing patient-reported outcomes after minimally invasive versus open surgery for degenerative grade 1 lumbar spondylolisthesis.

Journal of neurosurgery. Spine·2026

Comparative evaluation of oral versus intravenous antibiotic prophylaxis prior to obstetric and gynecological procedures.

Bioinformation·2026

Comparative evaluation of single-incision laparoscopic surgery versus conventional laparoscopic surgery.

Bioinformation·2026

Concomitant surgical ablation for atrial fibrillation in mitral valve surgery: a systematic review of clinical outcomes and surgical strategies.

Frontiers in cardiovascular medicine·2026

Feasibility and clinical efficacy of minimally invasive techniques in the treatment of type Ⅱ/Ⅲ brucellar spondylitis.

Frontiers in surgery·2026

Surgical site infection incidence and surgical antibiotic prophylaxis in the ICU patient: a multicenter observational study.

Journal of intensive care·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us